Valneva SE
Valneva SE's revenue rose 3.0% to €175 million in fiscal 2025. Its operating margin was −47.0%, down from 7.9% a year earlier. Free cash flow was −€57 million. The diluted share count rose 15.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Income statement
Valneva SE lost money in fiscal 2025: a net loss of €115 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 347 | 286 | 126 | 168 | 110 |
| Debt incl. finance leases | 65 | 99 | 177 | 187 | 179 |
| Net debt (negative means net cash) | −282 | −188 | 51 | 19 | 70 |
| Net debt to EBITDA | — | — | — | 0.6x | — |
| Debt to equity | 0.4x | 0.5x | 1.4x | 1.0x | 1.7x |
| Interest coverage | −3.6x | −6.0x | −3.5x | 0.6x | −2.0x |
| Current ratio | 1.6x | 1.5x | 1.6x | 2.6x | 2.4x |
| Quick ratio | 1.2x | 1.4x | 1.4x | 2.1x | 1.9x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 4 of 9 | 1 of 9 |
| Rule of 40 | −198.6% | −37.5% | −29.8% |
| Altman Z'' | — | — | — |
| Accruals ratio | 18.7% | 11.4% | −13.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Fail | Fail | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 3 of 9 | 4 of 9 | 1 of 9 |
Compare
Put Valneva SE side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Valneva SE | FY25 | 3.0% | −47.0% | −32.8% | −34.5% | — | 1 | |
| Regenxbio | FY25 | 104.5% | −94.6% | −74.2% | — | — | — | Compare |
| Macrogenics | FY25 | −0.3% | −48.7% | −55.5% | — | — | — | Compare |
| Karyopharm Therapeutics | FY25 | 0.6% | −62.1% | −51.6% | — | — | 2 | Compare |
| Beam Therapeutics | FY25 | 120.0% | −274.6% | −257.6% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 126 | 110 | 348 | 361 | 154 | 170 | 175 |
| Revenue growth | — | −12.6% | 215.5% | 3.8% | −57.5% | 10.3% | 3.0% |
| Gross profit | 73 | 56 | 160 | 37 | 53 | 71 | 68 |
| Research and development | 38 | 84 | 173 | 105 | 60 | 74 | 85 |
| Operating income | −1 | −55 | −61 | −113 | −82 | 13 | −82 |
| Net income | −1 | −55 | −61 | −143 | −101 | −12 | −115 |
| Diluted EPS (EUR) | −0.02 | −0.71 | −0.75 | −1.24 | −0.73 | −0.08 | −0.68 |
| Diluted shares (millions) | 92 | 91 | 98 | 116 | 139 | 146 | 168 |
| Cash flow | |||||||
| Cash from operations | 6 | 138 | 77 | −245 | −203 | −67 | −53 |
| Capital expenditure | 10 | 19 | 92 | 29 | 14 | 14 | 4 |
| Free cash flow | −5 | 119 | −15 | −275 | −217 | −81 | −57 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 11 | 0 | 0 |
| Stock-based compensation | — | 6 | 14 | −9 | 5 | 8 | 10 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 64 | 204 | 347 | 286 | 126 | 168 | 110 |
| Debt incl. finance leases | — | 53 | 65 | 99 | 177 | 187 | 179 |
| Total assets | — | 449 | 817 | 621 | 460 | 500 | 399 |
| Total liabilities | — | 372 | 647 | 402 | 332 | 319 | 293 |
| Shareholders' equity | 135 | 77 | 171 | 220 | 128 | 181 | 106 |
| Margins and ratios | |||||||
| Gross margin | 58.2% | 50.8% | 46.0% | 10.2% | 34.4% | 41.9% | 38.7% |
| Operating margin | −0.6% | −50.0% | −17.6% | −31.4% | −53.4% | 7.9% | −47.0% |
| Net margin | −0.6% | −50.0% | −17.6% | −39.7% | −66.0% | −7.2% | −66.0% |
| Free cash flow margin | −3.9% | 107.7% | −4.4% | −76.0% | −141.2% | −47.8% | −32.8% |
| Rule of 40 (growth + FCF margin) | — | 95.1% | 211.1% | −72.2% | −198.6% | −37.5% | −29.8% |
| Return on capital | — | — | — | — | −61.4% | 5.5% | −34.5% |
| Return on equity | — | — | −49.5% | −73.4% | −58.3% | −7.9% | −80.2% |
| Return on assets | — | — | −9.7% | −19.9% | −18.8% | −2.5% | −25.6% |
| Net debt to EBITDA | — | — | — | — | — | 0.6x | — |